Samsung Biologics’ union workers began a five-day strike over wage disputes after a April rally and near-unanimous voting among union members. The work stoppage raises near-term operational risk for a major contract development and manufacturing organization supplying biologics production. For biotech customers, any interruption at a key site can propagate into fill-finish schedules, batch releases, and downstream clinical trial timelines depending on inventory and contract terms. The situation also underscores how labor and compensation issues are increasingly material to manufacturing continuity planning. Investors and operational stakeholders will be focused on the scope of impact—whether production can be partially maintained and how delays affect committed deliverables.